102 related articles for article (PubMed ID: 8171164)
21. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
23. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
Heaton KM; Ju G; Grimm EA
Ann Surg Oncol; 1994 May; 1(3):198-203. PubMed ID: 7842289
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
25. Lysis of herpes simplex virus-infected cells by lymphokine-activated killer cells.
Chu CT; Lee P; Lin BJ; Sun MJ; Hsieh KH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Feb; 24(1):108-18. PubMed ID: 1657543
[TBL] [Abstract][Full Text] [Related]
26. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
30. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
Nano R; Capelli E; Gerzeli G
Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
[TBL] [Abstract][Full Text] [Related]
31. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
32. Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.
Kuppen PJ; Eggermont AM; Marinelli A; de Heer E; van de Velde CJ; Fleuren GJ
Cancer Immunol Immunother; 1991; 33(1):28-32. PubMed ID: 2021956
[TBL] [Abstract][Full Text] [Related]
33. Substance P increases in vitro lymphokine-activated-killer (LAK) cell cytotoxicity against fresh colorectal cancer cells.
Flageole H; Senterman M; Trudel JL
J Surg Res; 1992 Nov; 53(5):445-9. PubMed ID: 1279274
[TBL] [Abstract][Full Text] [Related]
34. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
35. Responsiveness of murine lymphokine-activated killer activity to prostaglandin E2 at late phase of interleukin-2 induction.
Kokudo S; Chu TM
Tumour Biol; 1993; 14(3):144-54. PubMed ID: 8210948
[TBL] [Abstract][Full Text] [Related]
36. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors.
Jadus MR; Good RW; Crumpacker DB; Yannelli JR
J Leukoc Biol; 1991 Feb; 49(2):139-51. PubMed ID: 1991997
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
[TBL] [Abstract][Full Text] [Related]
38. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
39. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
Kanaoka Y; Umesaki N
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]